HealthCare Institute of New Jersey statement on FDA’s Commissioner’s National Priority Voucher (CNPV) program
HealthCare Institute of New Jersey statement on FDA’s Commissioner’s National Priority Voucher (CNPV) program
Trenton, June 19, 2025 ― Chrissy Buteas, President and Chief Executive Officer of the HealthCare Institute of New Jersey (HINJ – www.hinj.org), issued the following statement concerning this week’s announcement of the Food and Drug Administration (FDA)’s Commissioner’s National Priority Voucher (CNPV) program for accelerating FDA approvals:
“Researching and discovering a new treatment or cure can take a decade or longer and cost billions of dollars. The most important priority is to ensure a product is safe and effective for patients. Researchers, clinicians and government regulatory agencies work collaboratively to review all available data – from lab bench to clinical trials to post-market reviews – to confirm product safety and efficacy.”
Buteas continued, “Anything that can shorten a review period without compromising safety and efficacy means patients will benefit from new discoveries even sooner. Our companies will continue to partner with FDA and other stakeholders to deliver our life-saving treatments and cures to patients as quickly and as safely as possible.”
# # #
About the HealthCare Institute of New Jersey (HINJ)
Founded in 1997, the HealthCare Institute of New Jersey (HINJ) is a trade association that serves as the voice for our state’s leading research-based biopharmaceutical and medical technology companies. HINJ strives to raise awareness, understanding and public support for the state’s life sciences industry, expand patient access to the medical innovations our member companies produce and promote awareness of the life sciences’ economic impact in New Jersey.
To learn more, please visit www.hinj.org and follow us on X, Facebook and LinkedIn. For data on the life sciences’ impact on New Jersey’s economy, visit our By the Numbers page.
